Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Haemonetics is a global leader in plasma apheresis, operating in a $1 billion addressable market that is expected to grow at least in the mid-single digits [3] - The company emphasizes its strong position in the plasma apheresis market, which provides a durable source of EBITDA, attractive return on invested capital, and robust free cash flow [3] Growth Strategy - To accelerate growth and reduce volatility, Haemonetics has decided to diversify into attractive med-surg markets while avoiding competition with therapeutic category leaders [4] - The company aims to acquire and grow a portfolio of scalable, therapeutically agnostic enabling technologies in various medical and surgical areas [4]